Activated Donor T Cells Aim to Prevent GvHD After Stem Cell Transplant
First clinical trial tests activated regulatory T cells from healthy donors to prevent graft-versus-host disease in stem cell transplant patients.
Researchers have reported the first clinical trial of a cell therapy built from activated regulatory T cells, known as ATregs or Actileucel, which are derived from white blood cells of healthy blood donors. The treatment is designed to prevent graft-versus-host disease (GvHD), a potentially severe complication that can arise after allogeneic stem cell transplantation.
GvHD occurs when donor immune cells attack the recipient's body. By infusing activated regulatory T cells, the therapy aims to calm that immune response and lower the risk of tissue damage. The trial marks an early but notable step in testing whether donor-derived regulatory cells can be used safely in this setting.
According to the source, this is the first clinical trial for this particular approach. As with any initial study, further research will be needed to confirm how well it works and to establish its safety profile. No other sources were available for comparison, so the findings stand as a single report rather than a consensus.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.